Aberrant Expression of BUB1B Contributes to the Progression of Thyroid Carcinoma and Predicts Poor Outcomes for Patients

Hai-chao Yan, Cheng Xiang

Department of Thyroid Surgery, The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang, China.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Objective: This study aimed to clarify the function and potential mechanism of BUB1B in THCA.

Methods: Expression of BUB1B in THCA was firstly determined, and its important prognostic value was then demonstrated. The potential mechanism was initially predicted by KEGG analysis. To explore the specific function of BUB1B in THCA, we used lentivirus infection to knock down the BUB1B, and then performed flow cytometry, colony formation, transwell, and wound-healing assays. Related protein expression was detected through western blotting. Additionally, we predicted the BUB1B-regulated pathways involved in THCA by GSEA analysis.

Results: BUB1B expression was highly increased in THCA tissues relative to normal controls. We further found that BUB1B was essential for tumor cell proliferation, and BUB1B high expression predicted a shorter PFS time of THCA patients. More importantly, Cox regression determined the BUB1B as an independent prognostic factor for PFS in THCA. BUB1B was initially found to participate in the cell cycle pathway from KEGG analysis. Unexpectedly, we did not detect the disturbing effect on the cell cycle distribution of THCA cells with BUB1B knockdown. But, BUB1B knockdown inhibited the proliferation, invasion, and migration of THCA cells, as well as increased apoptotic cells, and the results were further confirmed by western blotting. Through GSEA analysis, we predicted a positive correlation between BUB1B and metastasis-related pathways such as mTOR and NF-kappa B signaling pathways.

Conclusions: Present study identified BUB1B as a promising clinical prognostic factor in THCA, as well as a potential novel therapeutic target for cancer treatment.

Key words: thyroid carcinoma; BUB1B; high expression; prognosis; mechanism

Introduction

Thyroid carcinoma (THCA) is the most prevalent malignancy of the endocrine system, and its incidence is gradually increasing worldwide [1]. Although the 10-year survival rate of THCA patients was larger than 95%, 5–20% of patients were still subject to disease recurrence and distant metastasis [2]. Especially, the most aggressive type of THCA, anaplastic thyroid carcinoma showed a poor prognosis with a 39% survival rate at 1 year [3]. With the development of sequencing technology, research on THCA is progressing at the genetic level. It has been found that many genes were related to the occurrence, development, and prognosis of THCA. Zhao et al. performed a meta-analysis of case-control study and found a strong relationship between elevated concentrations of tumor necrosis factor-alpha (TNF-α) and THCA [4]. Lv et al. identified 4 methylation-driven genes in THCA with independent prognostic value, which provided new insight into molecular mechanisms of THCA [5]. Ma et al. revealed 2 RNA binding proteins were independently associated with the prognosis of patients with THCA.
and significantly affected cancer cell proliferation and migration [6]. Zhao et al. found that down-regulation of glucose-regulated protein GRP78 could significantly inhibit the metastatic and proliferative ability of THCA cells [7]. Cyclin E2 (CCNE2), exerting an important role in controlling the transition of quiescent cells into the cell cycle, regulating the G1/S transition, and promoting DNA replication, which has been proved to lead to carcinogenesis and the development of THCA [8]. There is an urgent need for identifying more specific biomarkers to reveal the pathogenesis of THCA.

It is commonly known that the cell mitosis process plays a crucial role in maintaining body functions. Spindle assembly checkpoint (SAC) has become an important monitor in the process of cell division, as it plays a vital role in arresting cell division until the precise chromosome segregation is ensured during mitosis and meiosis to maintain genomic stability [9]. Abnormal expression of SAC proteins can lead to the instability of chromosomes and promote cell malignant transformation. BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) is a key regulator of the SAC family [10]. Growing evidence has demonstrated that aberrant expression of BUB1B was highly involved in the tumorigenesis and development of various tumors. Scintu et al. demonstrated an increase of BUB1B transcripts in the majority of ductal breast carcinoma samples, and BUB1B mRNA levels correlated with intrachromosomal instability [11]. A high expression of BUB1B was also found in prostate cancer, indicating that BUB1B was essential for efficient tumor cell proliferation and correlated with poorer patient outcomes [12]. In addition, BUB1B has been identified as the top-scoring glioblastoma lethal kinase, and knockdown of BUB1B inhibited the expansion of brain tumor-initiating cells isolates [13]. It followed that BUB1B significantly participated in the tumor progression.

From the aspect of clinical value, a meta-analysis has demonstrated that BUB1B was a significant biomarker for a poor prognosis and poor clinicopathological outcomes in patients with lung adenocarcinoma [14]. BUB1B has been determined as a useful prognosis biomarker in several human cancers such as colon cancer [15], colorectal cancer [16], gastric cancer [17], and hepatocellular carcinoma [18]. In addition, combined expression of BUB1B and others genes were also proved to be a strong predictor of overall survival in adult adrenocortical tumors [19]. These researches suggested the importance of BUB1B in tumor progression and significant prognostic value on patient survival. At present, only two studies by bioinformatics analysis revealed BUB1B as a hub gene in anaplastic thyroid carcinoma [20, 21]. However, the detailed function and role of BUB1B in THCA have not been revealed up to now.

In this study, we discovered that BUB1B was highly expressed in THCA tissue compared with normal tissue. Kaplan-Meier and Cox regression analyses uncovered the independent prognostic value of BUB1B high expression for predicting a shorter progression-free survival in THCA patients. We further determined that BUB1B was involved in THCA progression by influencing the proliferation, apoptosis, invasion, and migration of THCA cells. Our study initially and systematically demonstrated the importance of BUB1B in THCA and revealed the possible mechanism associated with BUB1B in THCA.

**Materials and Methods**

**Expression analysis and verification of BUB1B in THCA**

We firstly evaluated the mRNA expression of BUB1B in THCA and normal samples by analyzing the mRNA expression profile of THCA patients, which was obtained from the TCGA database. The protein expression of BUB1B and its subcellular location in THCA were further detected by immunohistochemistry and immunofluorescence. We obtained thyroid tissue samples consisting of the tumor tissues and normal tissues from The Second Affiliated Hospital of Zhejiang University College of Medicine. All specimens were handled and made anonymous according to ethical and legal standards. Our study obtained the consent of the Ethics Committee of the The Second Affiliated Hospital of Zhejiang University College of Medicine before the research began.

**Prognosis and genetic alteration analysis of BUB1B in THCA**

We then explored the prognostic value of BUB1B in THCA patients based on TCGA data. The inclusion criteria: (a) samples diagnosed as thyroid cancer; (b) samples with mapped clinical information and gene expression matrix; (c) samples with complete clinical information including survival time, survival status, age, and gender. The exclusion criteria: (a) normal tissue samples; (b) samples without complete clinical information; (c) samples with no expression value; (d) samples with bias in expression value. This study evaluated the prognostic impact of BUB1B expression on the overall survival (OS) and progression-free survival (PFS) of THCA patients via Kaplan-Meier survival analysis. Restrict survival analysis was performed based on the patient's age, gender and clinical stage. Cox regression analysis was used to
predict the independent prognostic value of BUB1B in THCA. We also explored the mRNA expression and prognostic impacts of BUB1B in various human cancers in the GSCA database. In addition, genetic alteration of genes is one of the causes affecting cancer development. Hence, we further assessed the genetic alteration of BUB1B in THCA (TCGA, Firehose Legacy) in the cBioportal database which contained 397 samples with complete genetic alteration data, and explored the somatic mutation of BUB1B in the COSMIC database.

**Combined effect exploration of BUB1B and TOP2A in THCA**

To further verify the importance of BUB1B in clinical, we explored the combined effects of BUB1B with other gene on the prognosis of THCA patients. From cBioportal database, Topoisomerase (DNA) II Alpha (TOP2A) showed the largest correlation with BUB1B. We then detected the relationship between them in TIMER database and western blotting. The mRNA expression of TOP2A in THCA was evaluated in GSCA database. The prognostic effect of TOP2A on the PFS of THCA patients were evaluated through Kaplan-Meier analysis using the TCGA-THCA data. Independent prognostic value of TOP2A in THCA was assessed through Cox regression analysis. Subsequently, we assessed the combined the prognostic impacts of 2 genes on the PFS of THCA patients.

**Enrichment analysis on BUB1B co-expressed genes**

For revealing the potential mechanism of BUB1B in THCA, we firstly obtained the co-expressed genes with BUB1B in THCA through the cBioportal database. The genes with absolute correlation coefficient>0.5 and P<0.05 were selected for the further enrichment analysis containing GO annotation and KEGG pathway prediction. GO annotation analysis contained biological process (BP), cellular component (CC), and molecular function (MF) exploration. KEGG analysis was used to predict the potential pathways associated with these genes. We used the clusterProfiler R package to perform the enrichment analysis.

**Immunofluorescence assay**

The THCA cell slides were fixed with 4% paraformaldehyde for 20 min and incubated with 5% BSA solution at room temperature for 90 min. The diluted primary and secondary antibodies were successively taken to incubate the slides. The slides were then washed with PBS, and DAPI was added to stain the nucleus for 5 min. After rinsing slides with PBS, phalloidine was diluted with PBS and added to slides, followed incubation for 20 min. Finally, the immunofluorescence images were obtained.

**Cell culture and plasmid transfections**

Two human cell lines (BCPAP and TPC-1) of human thyroid carcinoma was obtained from BeNa Technology (Hangzhou) were used for conduct experiment. The BCPAP and TPC-1 cells were cultured in Dulbecco’s modified Eagle’s medium DMEM (HyClone) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 g/ml streptomycin at 37 °C with 5% CO2. Three small interfering RNA (siRNA) were designed and constructed for inhibiting BUB1B/TOP2A expression (siRBU1B/siRTOP2A) (Table 1). Before transfection, we mixed 2 μl Lipofectamine 2000 and 50 μl Opti-MEM as solution 1 and mixed 100 nMsilDNA and 50 μl Opti-MEM as solution 2. Then, the THCA cells were transfected for 24-48 h with miscible liquids of solution 1 and solution 2. The knockdown efficiency was determined by western blot.

**Cell viability detection**

After transfection for 24 and 48h with siRNA, the cells were harvested and counted on a hemocytometer. The MTT assay was utilized to assess cellular proliferative potential based on the manufacturer's protocol. In brief, we planted the stable cell lines into 96-well plates (1000-10000 cells/well). After incubation for 3 hours at 37°C in the incubator described above, we measured the absorbance (570 nm) of each well and obtained the optical density (OD) value.

**Apoptosis assay**

We used the Annexin V-FITC/propidium iodide (PI) Apoptosis Detection Kit to identify apoptotic cells based on the manufacturer's protocol. The cells were firstly collected with trypsin without EDTA and then rinsed with PBS. The 100 μl cell suspension was

| Table 1. Three differential small interfering RNA sequences. |
|-------------------------------------------------------------|
| siRNA | sense | antisense |
|-------|-------|-----------|
| siR-Nc | UUCUCGAAACGACUGUCGGA | ACCUGACUCGGUGUCGAGAAT |
| siR-BUB1B-1 | CGUCAUUUGUUCGUCCCAA | UAUAUGUGCGGAAAGCUAC |
| siR-BUB1B-2 | GAGACACUUAACUGGAAAU | AUAAUGUCAGGGUAGUGUC |
| siR-BUB1B-3 | CCGUGCCAGGAAUUGCAAG | UAUCUGAGAACACAGAGCU |
| siR-TOP2A-1 | ACUGGUCGCAAGUCAUA | UAAAUCUCAACAGGUCCT |
| siR-TOP2A-2 | AGCCCUUGUGCCGCAUGUA | UAAAUCUCAACAGGUCCT |
| siR-TOP2A-3 | ACCUGUUUGUUGGCAUGGA | UAAAUCUCAACAGGUCCT |

https://www.jcancer.org
placed to a 5 ml tube, and then 5 μl Annexin V/FITC solution was added. After adding 10 μl PI solution (20 μg/ml) and 400 μl PBS, the apoptosis level of cell samples was immediately detected by the flow cytometry.

**Cell cycle assay**

The cell cycle distribution was detected by flow cytometry. We first digested the stable cell lines with trypsin for 2 min, then added DMEM to the culture dish to stop the digestion. We collected the cell suspension and centrifuged them at 400 g for 5 min. After rinsing the cell lines, we discarded the PBS and first fixed the cell with 750 μl of 75% ethyl alcohol for 18-24h at 4°C. We then collected the cell lined after centrifugation at 300 g for 5 min. Subsequently, the cells were incubated with 2.5μl RNase and 25 μl PI solution for 30 min at room temperature. The cell cycle distribution was detected within 24 h.

**Colony formation assay**

We seeded the cell lines into 6-well plates. After culturing all cells with DMEM for 10 days, we cultured the cell media and washed the cells with PBS two times. Then we fixed the cells with 0.8ml methanol for 20 min. Finally, we stained the cells with 0.8ml crystal violet dye solution and 0.8ml methanol for 20 min. Finally, we stained the colonies with an inverted microscope.

**Transwell invasion assay**

The 100μl Matrigel solution was firstly spread out in the upper chambers, and the cell suspension (100 μL) was then added to the upper chambers. The lower chamber contained 500 μl 10% fetal bovine serum used as a chemoattractant. After incubation for 24 h at 37°C, cells were fixed with methanol for 20 min and then stained with crystal violet dye solution for 40 min. Finally, the images for transwell invasion were obtained by an inverted microscope.

**Wound-healing assay**

The scratch wound-healing motility assay was performed to evaluate the migration ability of THCA cells. The transfections with BUB1B or negative control plasmids were carried out when the cell reached 80%-90% confluence. The 24 h and 48 h after the transfection, a scratch was made with a 10 μL pipette tip. The cells were then returned to the incubator until the indicated time. Representative sites were photographed, and the cells that migrated from the wound edge were counted at each time point.

**Western blotting analysis**

The proteins were extracted for Western blot analyses after 24 and 48h transfection. Western blotting was performed on the basis of the manufacturer's instructions and related information as previously described. The antibodies used for western blotting in this study are described in Table 2.

| Table 2. List of antibodies used |
|--------------------------------|
| protein name | Company | Art. No. | Protein | Company | Art. No. |
| BU861(BUB1B) | Abcam | ab185496 | CDK2 | CST | ab32147 |
| TOP2A | Abcam | ab52934 | P53 | CST | 2925 |
| CDK1 | Abcam | ab133327 | CyclinB1 | Abcam | ab32053 |
| Bcl-2 | CST | 15071 | Caspase3 | Abcam | ab13847 |
| Caspase-9 | CST | 9502 | Caspase7 | Proteintech | 271555-1-AP |
| MMP2 | CST | 878989 | MMP9 | Abcam | ab76003 |
| Vimentin | CST | 5741 | N-cadherin | Proteintech | 22018-1-AP |
| Goat anti-Mouse IgG Antibody | CST | 7076 | Goat anti-Rabbit IgG Antibody | CST | 7074 |
| β-actin | CST | 4970 | E-cadherin | Abcam | ab32053 |
| GAPDH | CST | 5374 | | Abcam | ab13847 |

**Statistical analysis**

The data in this study were analyzed with SPSS 23.0. All experiments were repeated three times and related data were expressed as mean±SD. Statistical differences of quantitative data between groups were evaluated using the Student’s t-test or one-way analysis of variance (ANOVA). The qualitative data between groups was compared with χ² test. Survival difference between groups was compared with the Kaplan-Meier method and log-rank test. Independent prognostic analysis was performed with Cox regression. Correlation between 2 genes was detected with the spearman method. P<0.05 was regarded as the statistical significance.

**Results**

**BUB1B is highly expressed in THCA and associated with tumor progression**

We firstly evaluated the mRNA expression of BUB1B in normal and THCA tissues based on TCGA-THCA data. The differential expression analysis showed that BUB1B mRNA was highly expressed in THCA tissues compared with that in normal tissues (Fig. 1A, P<0.001), and BUB1B high expression in THCA was confirmed through paired samples analysis as well (Fig. 1B, P=0.003). In addition, the protein expression of BUB1B in clinical normal and cancer samples was detected by the immunohistochemistry method and presented in Fig. 1C. From the HPA database in our previous
investigation, we found that BUB1B was mainly located at cytosol (data not shown), and its subcellular location in THCA cells was also detected in vitro in our study by immunofluorescence (Fig. 1D). In addition, we found BUB1B variation in the transcript (Fig. 1E) and protein (Fig. 1F) expression correlated to the cell cycle.

We also explored the correlation between BUB1B mRNA expression and the clinical futures of patients based on TCGA data. All patients were assigned into low and high expression groups according to BUB1B median expression, then we assessed the expression difference of BUB1B under different clinical characteristics by qualitative analysis (Table 3). We subsequently evaluated the detailed expression level of BUB1B in various clinical futures of patients by quantitative analysis, and the results showed that patient’s age, gender, T stage, N stage, M stage, clinical stage, neoplasm depth, length, and width did not influence BUB1B mRNA expression (Fig. 2).

To investigate the effects of abnormal BUB1B expression in THCA cells, siRNAs specific for BUB1B were used to deplete the expression of BUB1B in BCPAP and TPC-1 cells, for 24 and 48 h. The knockdown efficiency was verified by western blot (Fig. 3A, 3B), founding that cell viability was significantly decreased in the BUB1B-knockdown group compared with other groups after 48h knockdown (Fig. 3C). These results suggested that BUB1B might be involved in the growth of THCA cells. On account of possessing the highest knockdown efficiency in 2 type cells, the siR3 was chosen for all subsequent experiments.

Figure 1. Expression analysis of BUB1B in THCA. (A) mRNA expression of BUB1B in normal and THCA samples (TCGA). The two-sample t test was used to compare the difference between 2 groups. (B) mRNA expression of BUB1B in paired normal and THCA samples (TCGA). The paired t test was used to compare the difference between 2 groups. (C) The protein expression of BUB1B in normal and tumor tissues by immunohistochemistry method. (D) Location verification of BUB1B by immunofluorescence. (E) BUB1B mRNA expression across cell cycle (HPA). (F) BUB1B protein expression across cell cycle (HPA). Abbreviation: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.

https://www.jcancer.org
Figure 2. Association of BUB1B mRNA expression with clinical clinicopathological features of THCA patients. Abbreviation: THCA, thyroid carcinoma; T, tumor topography; N, lymph node metastasis; M, distant metastasis; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; The two-sample t test was used to compare the difference between 2 groups, and one-way ANOVA was used to compare the difference among large than 2 groups.

Figure 3. The effect of BUB1B on tumor cell growth. The (A) and (B) indicated the knockdown efficiency of BUB1B in THCA cell lines through western blot. (C) Cell proliferation in THCA cell lines with BUB1B knockdown was assessed with MTT assay. The two-sample t test was used for difference comparison between 2 groups (BK vs siR-NC, siR-NC vs siR-BUB1B). Abbreviation: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.
The above results have indicated BUB1B high expression in THCA and its influence on tumor cell growth, we further evaluated its prognostic impact on THCA patients. The BUB1B expression did not influence the overall survival of patients (Fig. 4A, P=0.72), but THCA patients with higher BUB1B expression were characterized by a shorter progression-free survival (P=0.0042). Further restrict survival analysis based on the patient’s age, gender, and the clinical stage was performed and presented in Table 4.

Additionally, among 33 cancer types, BUB1B higher expression caused a worse overall survival and shorter progression-free survival time in one-third of types (Fig. 4B, all HR>1, all P<0.05). The favorable prognostic impact of BUB1B in 33 cancer types was not observed. Even more, unfortunately, BUB1B was highly expressed in almost all cancers types including THCA (Fig. 4C). These results suggested that BUB1B acted as an oncogene and its abnormal high expression exerted a vital influence on cancer patient’s survival including THCA.

In addition, the Cox proportional hazards regression model was used for univariate and multivariate analyses (Table 5). The univariate and multivariate analyses indicated that upregulation of BUB1B was an independent predictor for shorter progression-free survival in THCA (all HR>1, all P<0.05). However, the upregulation of BUB1B could not predict shorter overall survival both in univariate and multivariate analyses (all P>0.05).

Taken together, our results indicated that BUB1B expression was upregulated in THCA and significantly associated with tumorigenesis. BUB1B high expression could independently predict a shorter progression-free survival of THCA patients. The above results suggested that BUB1B was probably involved in the tumorigenesis and progression of THCA and a likely prognostic biomarker for THCA.

### Table 3. The clinical characteristics of THCA patients based on TCGA data

| Parameters             | Number | Subtypes | Low (n=455) | High (n=455) | χ² | P  |
|------------------------|--------|----------|-------------|-------------|----|----|
| person neoplasm        | 435    | tumor free | 201         | 199         | 2.212 | 0.160 |
| cancer status          | 504    | with tumor | 15           | 22          | 0.038 | 0.922 |
| age                    | 504    | ≥55       | 176          | 178         | 0.160 | 0.764 |
|                        |        | >55       | 75           | 74          |      |    |
| gender                 | 504    | male      | 67           | 71          |      |    |
|                        |        | female    | 185          | 181         |      |    |
| T stage                | 502    | T1        | 74           | 67          | 3.747 | 0.290 |
|                        |        | T2        | 90           | 75          |      |    |
|                        |        | T3        | 78           | 96          |      |    |
|                        |        | T4        | 10           | 12          |      |    |
| N stage                | 455    | N0        | 124          | 103         | 6.172 | 0.015 |
|                        |        | N1        | 98           | 130         |      |    |
| M stage                | 294    | M0        | 140          | 146         | 0.003 | 0.953 |
|                        |        | M1        | 4            | 4           |      |    |
| clinical stage         | 502    | Stage I   | 132          | 152         | 11.172 | 0.011 |
|                        |        | Stage II  | 37           | 15          |      |    |
|                        |        | Stage III | 56           | 55          |      |    |
|                        |        | Stage IV  | 25           | 30          |      |    |
| radiation therapy      | 448    | no        | 85           | 84          | 0.039 | 0.846 |
|                        |        | yes       | 143          | 136         |      |    |
| neoplasm depth         | 403    | ≤1        | 46           | 57          | 0.684 | 0.710 |
|                        |        | 1-2       | 74           | 77          |      |    |
|                        |        | ≥2        | 74           | 75          |      |    |
| neoplasm length        | 475    | 3-6       | 154          | 145         | 1.564 | 0.457 |
|                        |        | ≥6        | 14           | 20          |      |    |
| neoplasm width         | 425    | ≤2        | 105          | 119         | 4.866 | 0.101 |
|                        |        | 2-4       | 83           | 70          |      |    |
|                        |        | ≥4        | 18           | 30          |      |    |
| progression-free       | 504    | without   | 237          | 214         | 11.154 | 0.001 |
| survival status        |        | recurrence |            |             |      |    |
| overall survival       | 504    | alive     | 243          | 245         | 0.258 | 0.800 |
| status                 |        | dead      | 9            | 7           |      |    |

### Table 4. Kaplan-Meier analysis in terms of PFS on BUB1B in THCA

| Parameters             | Low (N=192) | High (N=192) | HR (95% CI) | Log-rank P |
|------------------------|-------------|-------------|-------------|------------|
| clinical stage         |             |             |             |            |
| I                      | 142         | 142         | 3.09 (1.12-8.50) | 0.02       |
| II                     | 26          | 26          | 0.79 (0.13-4.75) | 0.80       |
| III                    | 55          | 56          | 1.83 (0.66-5.05) | 0.23       |
| IV                     | 27          | 28          | 4.65 (1.19-18.13) | 0.03       |
| gender                 |             |             |             |            |
| male                   | 69          | 69          | 2.08 (0.83-5.22) | 0.11       |
| female                 | 183         | 183         | 3.88 (1.68-8.94) | 0.0061     |
| age                    | ≤55         | 177         | 2.64 (1.65-5.99) | 0.02       |
|                        | >55         | 75          | 2.94 (1.23-7.06) | 0.01       |

Abbreviation: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; N, sample number.

In addition to aberrant expression, mutation of BUB1B can cause aneuploidy, thus affecting cancer development. Hence, we also explored BUB1B genetic alteration in THCA. The 1.8% patients among 397 samples appeared genetic alteration with characteristics of mRNA high expression (Fig. 5A). BUB1B alteration based on cancer types was shown in Fig. 5B. The main mutation type of BUB1B in THCA was missense substitution (Fig. 5C). Single nucleotide variation for missense substitution was presented as T>C (Fig. 5D).

https://www.jcancer.org
Figure 4. Effects of BUB1B mRNA expression on the prognosis of patients. (A) Kaplan-Meier survival analysis on BUB1B in terms of OS and PFS in THCA. The survival difference between 2 groups was compared with log-rank test. (B) Survival difference between BUB1B high and low expression groups in 33 cancer types. The bubble plot presented the hazard ratio and Cox p-value through bubble color and size. The row is the gene set symbol, and the column is the selected cancer types. The bubble color from blue to red represents the hazard ratio from low to high, bubble size is positively correlated with the Cox P-value significance. The black outline border indicates Cox P-value≤0.05. (C) The mRNA expression of BUB1B in various human cancers. Abbreviation: THCA, thyroid carcinoma; OS, overall survival; PFS, progression-free survival; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.

Combined effect of BUB1B and TOP2A in THCA

The previous study has indicated the significant prognostic value of combined expression of BUB1B with several genes in human cancers; this study also explored the combined prognostic value of BUB1B with important genes in THCA. We detected all co-expressed genes of BUB1B in THCA, finding that TOP2A showed the largest positive correlation with BUB1B (Fig. 6A). We then explored the interaction between them by western blotting, finding that TOP2A protein expression was downregulated in THCA cells with BUB1B knockdown (Fig. 6G). Knockdown of TOP2A also caused the BUB1B expression to decrease (Fig. 6H). Survival analysis firstly showed that TOP2A high expression shortened the progression-free survival time of THCA patients (Fig. 6D, P<0.001). Expression analysis showed that TOP2A was highly expressed in THCA tissue compared with normal tissue (Fig. 6B), but its expression did not correlate with the clinical stage of THCA (Fig. 6C). These results indicated TOP2A as an oncogene in THCA. We further assessed the importance of TOP2A in THCA progression by Cox regression analysis, finding that TOP2A expression was an independent prognostic factor for progression-free survival of THCA patients (Table 6).

We further explored the combined prognostic impacts of BUB1B and TOP2A on PFS of THCA patients. Compared with all low-expression group, all high expression of 2 genes decreased the survival probability of patients (Fig. 6E). No difference in survival time was observed between all high-expression groups and the group with BUB1 high expression-TOP2A low expression (Fig. 6F). It followed that consistent low expression of BUB1B and TOP2A exerted a vital influence on the patient's survival. The detailed prognostic impacts on THCA patient needs further investigation in a clinical cohort.
Figure 5. The genetic alteration of BUB1B in THCA. (A) Genetic frequency of BUB1B among 397 THCA samples (cBioportal). (B) BUB1B genetic alteration based on detailed cancer type. (C) Overview of the types of mutation observed. (D) Breakdown of the observed substitution mutations. Abbreviations: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.

Figure 6. Combined effect exploration of BUB1B and TOP2A in THCA. (A) Spearman correlation analysis between BUB1B and TOP2A mRNA expressions in THCA (TIMER). (B) The mRNA expression of TOP2A in normal and THCA samples. (C) Correlation of TOP2A mRNA expression with clinical stage in THCA. (D) Effect of TOP2A expression on PFS time of THCA patients. (E) Prognostic impact analysis on THCA patient’s PFS with the combination of BUB1B and TOP2A. (F) PFS survival time difference between 2 groups. (G) TOP2A protein expression with BUB1B knockdown. (H) BUB1B protein expression with TOP2A knockdown. Abbreviation: THCA, thyroid carcinoma; PFS, progression-free survival; FDR, false discovery rate; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; TOP2A, Topoisomerase (DNA) II Alpha; all high: BUB1B high expression-TOP2A high expression; all low, BUB1B low expression-TOP2A low expression; B high-T low, BUB1B high expression-TOP2A low expression; NS, no significance.
**Figure 7.** Functional enrichment analysis on BUB1B co-expressed genes in THCA. Abbreviations: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; BP, biological process; MF, molecular function; CC, cellular component; KEGG, Kyoto Encyclopedia of Genes and Genomes.

**Table 6.** Cox regression analysis on TOP2A in terms of PFS in THCA patients

| Variables   | Univariate analysis | Multivariate analysis |
|-------------|---------------------|-----------------------|
|             | HR (95% CI)         | P         | HR (95% CI) | P  |
| TOP2A       | 1.506 (1.194-1.901) | 0.001     | 1.512 (1.195-1.914) | 0.001 |
| age         | 0.990 (0.971-1.016) | 0.545     | 0.999 (0.972-1.027) | 0.942 |
| stage       | 0.901 (0.647-1.254) | 0.536     | 0.896 (0.598-1.341) | 0.896 |
| gender      | 1.017 (0.477-2.171) | 0.965     | 0.990 (0.462-2.119) | 0.979 |

Abbreviation: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; TOP2A, Topoisomerase (DNA) II Alpha; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.

**Enrichment analysis on BUB1B**

Due to the importance of BUB1B in THCA, we next performed enrichment analysis to reveal its potential function (Fig. 7). A total of 123 co-expressed genes of BUB1B in THCA were firstly obtained by setting absolute spearman's correlation>0.5 and P<0.05. Subsequent GO analysis showed that these 123 genes were mainly located at spindle and chromosome (CC), and participated in cell division, nuclear division, and chromosome segregation processes (BP). The molecular function mainly referred to tubulin-related binding (MF). KEGG pathway analysis indicated that these genes possibly correlated with cell cycle and oocyte meiosis. Further information showed that BUB1B referred to the cell cycle pathway.

**BUB1B influences proliferation, migration, and apoptosis in THCA cells**

After silencing BUB1B, the THCA cell viability was significantly inhibited. From KEGG analysis, the cell cycle pathway was detected. To determine whether the above growth inhibitory phenotype was due to the disturbed cell cycle progression, we analyzed the cell cycle profile upon UBUB1B silencing by flow cytometry. However, we found no obvious influence of BUB1B knockdown on the cell cycle distribution of THCA cells (Fig. 8A). Cell cycle-related proteins were detected and presented as Fig. 8B.

Apoptosis alteration is one of the important factors in the progression and development of cancer. We performed flow cytometry to investigate the rate of apoptosis with BUB1B knockdown. Our results displayed that the knockdown of BUB1B promoted the apoptosis of BCPAP and TPC-1 cells (Fig. 9A). Based on the western blotting results, the proteins related to apoptosis appeared with no obvious changes in the BCPAP cell. But apoptosis-related protein levels were elevated in TPC-1 cell such as caspase 3, caspase 7, and caspase 9. The expression of anti-apoptotic protein Bcl-2 was not influenced in 2 cells (Fig. 9B). It followed that BUB1B knockdown influenced the apoptosis of THCA cells.

We also evaluated the potential effects of BUB1B on the proliferation and migration of THCA cells. First, the relationship between BUB1B and proliferating cell nuclear antigen (PCNA) was assessed. A positive relationship between the expression of BUB1B and PCNA was noticed (Fig. 10A). We have observed the decreased cell viability with BUB1B knockdown. The inhibition by BUB1B knockdown was also confirmed by colony formation assay, as knockdown of BUB1B contributed to a
notable decrease in the clonogenic survival of THCA cells (Fig. 10B). Next, we carried out a wound-healing assay for investigating the effect of BUB1B knockdown on THCA cell migration. The results suggested that the migration of BCPAP cell was significantly reduced upon BUB1B knockdown (Fig. 10C). No obvious inhibition was observed in TPC-1 cell. It followed that BUB1B was related to the proliferation and migration of THCA cells.

Transwell assay was used to explore the effect of BUB1B on migration and invasion of THCA cells. The cell density of 1W was firstly identified as the proper criterion after detecting the cell migration ability (Fig. 11A). As determined by transwell assay, siR-BUB1B treated cells have a lower invasive capacity than do control cells (Fig. 11B). TWIST1 can promote tumor cell invasion and metastasis, and act as a vital regulator in the EMT process. We also found a positive correlation between BUB1B and TWIST1 (Fig. 11C). From western blotting, MMP2, N-cadherin, and Vimentin were upregulated in the BUB1B knockdown group in 2 cells, while E-cadherin expression was down-regulated in BUB1B knockdown group (Fig. 11D). The change of MMP9 protein was not apparent in 2 THCA cells. These results demonstrated that BUB1B might regulate the migration and invasion of THCA cells.

Figure 8. Effects of BUB1B expression on cell cycle in THCA cells. (A) Cell cycle in THCA cell lines with BUB1B knockdown was analyzed by flow cytometry. The two-sample t test was used for difference comparison between 2 groups (Blank vs siR-NC, siR-NC vs siR-BUB1B). (B) Western blot analysis of cell cycle-related proteins in THCA cell lines with BUB1B knockdown. Abbreviations: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.
**Correlation between BUB1B and cancer pathways in THCA**

The above results have indicated that BUB1B might regulate the apoptosis, invasion, and migration of THCA cells. To further determine potential signaling pathways modulated by BUB1B, we performed GSEA analysis via analyzing the data from TCGA. We explored the correlation between BUB1B and migration pathways, observing that the activity of the mTOR, NF-kappa B, TGF-beta, and TNF signaling pathway was positively correlated with BUB1B expression levels in THCA tissues (Table 7). We have found the influence of BUB1B knockdown on cell apoptosis in vitro, and GSEA analysis confirmed a positive correlation between BUB1B and the apoptosis pathway. Although a significant positive regulation was observed between BUB1B and the cell cycle pathway, the disturbing effect of BUB1B knockdown on the cell cycle distribution of THCA cells was not detected in our flow cytometry assay.

**Table 7. Correlation of BUB1B with important cancer-related pathways involved in THCA by GSEA analysis**

| Pathway name          | NES    | P       |
|-----------------------|--------|---------|
| NF-kappa B signaling  | 1.9566 | 0.0019  |
| TGF-beta signaling    | 1.7434 | 0.0195  |
| Apoptosis             | 2.1453 | <0.0001 |
| mTOR signaling        | 1.8421 | 0.0035  |
| Cell cycle            | 2.4330 | <0.0001 |
| TNF signaling         | 1.9001 | 0.0034  |

Abbreviation: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; GSEA, gene set enrichment analysis; NES, normalized enrichment score; NF, nuclear factor; TGF, transforming growth factor; mTOR, mammalian target of rapamycin; TNF, tumor necrosis factor.

Figure 9. Effects of BUB1B expression on apoptosis in THCA cells. (A) Apoptosis of THCA cell lines with BUB1B knockdown was analyzed by flow cytometry. The two-sample t test was used for difference comparison between 2 groups (Blank vs siR-NC, siR-NC vs siR-BUB1B). (B) Western blot analysis of apoptosis-related proteins in THCA cells. Abbreviations: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.
Figure 10. Effects of BUB1B expression on proliferation and migration in THCA cells. (A) Correlation between BUB1B and PCNA (TIMER). (B) Cell proliferation in THCA cell lines with BUB1B knockdown was assessed with colony formation. (C) Wound-healing assays detected cell migration in THCA cell lines with BUB1B knockdown. The two-sample t test was used for difference comparison between 2 groups (BK vs siR-NC, siR-NC vs siR-BUB1B). Abbreviation: PCNA, proliferating cell nuclear antigen. Abbreviations: THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.

Figure 11. Effects of BUB1B expression on invasion and migration in THCA cells. (A) Cell density determination for Transwell assays. (B) Transwell assays detected cell migration and invasion of THCA cell lines with BUB1B knockdown. (C) Correlation between BUB1B and TWIST1. (D) Western blot analysis on migration-related proteins in THCA cell lines. Abbreviations: TWIST1, Twist Family BHLH Transcription Factor 1; THCA, thyroid carcinoma; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B.
Discussion

Although THCA patients have a better clinical outcome rather than other cancer types, the patients are always subject to recurrence risk of disease. The current diagnostic biomarkers still fail to predict the progression of THCA. Therefore, it is of great interest to develop novel biomarkers for the estimation of progression and recurrence potential. Herein, we reported that BUB1B mRNA were highly expressed in THCA samples, and BUB1B expression influenced the THCA cells' growth. Overexpression of BUB1B predicted a shorter progression-free survival time of THCA. Together, these results suggested that overexpression of BUB1B presented the potential to serve as a biomarker for THCA prognosis.

The BUB1B gene is located at chromosome 15q15. The function of BUB1B in mitosis includes activation, maintenance, and silencing the SAC as well as regulating chromosome-spindle attachment, and it is also required for controlling mitotic timing. Clausen et al. found that BUB1B expression was significantly reduced in aneuploid compared to diploid cancers [22], showing that loss of spindle checkpoint function may be involved in the development of DNA aneuploidy, and thus influenced the tumor progress. Aberrant expression or mutations of BUB1B can cause aneuploidy. The abnormal high expression of BUB1B has been revealed in sarcoma [23], breast cancer [24], and hepatocellular carcinoma [25]. Our study found high expression of BUB1B in THCA through bioinformatics and experimental verification in vitro, and BUB1B knockdown influenced the THCA cell growth. It followed that BUB1B might be involved in THCA progression. In terms of BUB1B mutation, Hanks et al. suggested that the genetic progression of BUB1B in rhabdomyosarcoma from mosaic variegated aneuploidy (MVA) and non-MVA cases may be similar, but that somatic BUB1B mutations were unlikely to be common in sporadic childhood cancers known to be associated with MVA [26]. Hahn et al. indicated that germine mutations in BUB1B were at high risk for the development of early-onset colorectal cancer [27]. Rio et al. reported that a germine homozygous intrinsic mutation of BUB1B increased the susceptibility to gastrointestinal oncogenesis [28]. It followed that BUB1B mutation was significantly related to tumor development. In this study, we observed the genetic alteration of BUB1B in THCA, indicating the potential influence on THCA development. Several mutations of BUB1B were associated with cancers such as M40T in colorectal cancer and Q563R in breast cancer [29]. However, we did not find the mutation site of BUB1B in THCA samples. BUB1B mutation not only correlated with tumor progression but also was detrimental to woman's health. Chen et al. found that heterozygous deleterious variants of BUB1B can be able to induce premature ovarian insufficiency and early menopause [30]. Apart from abnormal expression and mutation, polymorphisms in BUB1B may contribute to tumorigenesis and the risk of tumor development [31].

To further assess the importance of BUB1B in clinical, we explored the effect of BUB1B expression level on the prognosis of THCA patients. We found that BUB1B high expression shortened the progression-free survival time of THCA patients, but did not influence the patient's overall survival. High expression of BUB1B increased the recurrence risk of THCA patients. BUB1B has been identified as an immune-related gene in prostatic adenocarcinoma, acting as a component of risk signature, and exhibiting a good prognostic value and predictive accuracy [32]. BUB1B was also involved in the molecular regulation of EMT and associated with poor early survival of ovarian serous carcinoma at stages I+II [33], indicating BUB1B as a key biomarker for early clinical diagnosis and prognosis evaluation of patients. Jiang et al. constructed a model using 10 cell cycle-related genes including BUB1B, finding that signature could precisely predict the prognosis of lung adenocarcinoma patients [34]. These researches have presented the vital prognostic value of BUB1B in human cancers and revealed its potential as a useful therapeutic target. In this study, BUB1B was also proved to be an independent prognostic factor for PFS of THCA patients. The result further demonstrated the importance of BUB1B in THCA. It was worth mentioning that, we did not find a favorable prognostic impact of BUB1B high expression among 33 cancer types by pan-cancer analysis. Worse was that BUB1B was highly expressed in almost all cancers. It suggested that BUB1B might act as an oncogene and significantly affect the clinical outcome of patients.

From KEGG analysis for revealing the potential mechanism of BUB1B, we found that BUB1B was significantly related to the cell cycle pathway. However, we did not find an obvious disturbing effect of BUB1B on cell cycle distribution by flow cytometry in this study, and cell cycle-related proteins showed no apparent changes. Fu et al. found that BUB1B overexpression enhanced the proliferation, migration, and invasion ability of prostate cancer cells, whereas depletion of BUB1B did not affect the cell functions [35]. But our study conducted BUB1 knockdown and found that BUB1 knockdown inhibited the proliferation, migration, and invasion of
THCA cells. GSEA analysis indicated that BUB1B was positively correlated with metastasis-related pathways such as mTOR and NF-kappa B pathways. Qiu et al. found that BUB1B promoted hepatocellular carcinoma progression via activating the mTORC1 signaling pathway, and the oncogenic effect of BUB1B can be impaired when the mTORC1 signaling pathway was inhibited [25]. Harima et al. pointed that BUB1B was associated with tumor metastasis via chromosomal instability [36]. Several studies have suggested some useful biomarkers targeting BUB1B. By targeting BUB1B via shRNAs, BUB1B-dependent radioresistance can be decreased in glioblastoma [37]. Wan et al. has indicated that BUB1B was a direct transcriptional target of Forkhead Box M1 (FOXM1), and suppression of FoxM1 could reduce BUB1B expression and inhibit cell growth and survival [38]. Mechanistically, FOXM1 transcriptionally regulated BUB1B expression by binding to and then activating the BUB1B promoter [37]. He et al. found that miR-210 could suppress the expression of BUB1B by directly targeting its 3'-UTRs, and over-expression of exogenous miR-210 disturbed mitotic progression and caused aberrant mitosis [39]. It was highly necessary to detect more promising biomarkers targeting BUB1B, which was conducive to inhibit disease progression and improve patient’s clinical outcomes. This study revealed the function of BUB1B in THCA, revealing that BUB1B overexpression was unfavorable to the patient’s progression-free survival, and BUB1B knockdown affected the proliferation, invasion, and migration of THCA cells. But we failed to further confirm its function through other methods such as overexpression analysis. We did not find the disturbing effect of BUB1B on the cell cycle distribution of THCA cells, which was unexpected for us as BUB1B is a known cell cycle-related gene. Therefore, more verification methods were needed to detailly reveal the function of BUB1B. This is one of the limitations of this study. In addition, we predicted several metastasis-related pathways, and it will be better if the experimental verifications are further conducted.

Conclusions

In this study, the high expression of BUB1B in THCA tissues was confirmed by bioinformatic analysis and experimental verification in vitro. We found that BUB1B knockdown influenced the THCA cell growth and BUB1B high expression predicted a shorter progression-free survival, which suggested that BUB1B might be involved in THCA progression. KEGG analysis initially predicted that BUB1B was related to the cell cycle pathway, but a disturbing effect on THCA cells caused by BUB1B knockdown was not detected in our study. However, BUB1B knockdown influenced the proliferation, invasion, and migration of THCA cells. We further predicted a positive correlation between BUB1B and metastasis-associated pathways. It should be noted that BUB1B might be also involved in THCA development by combining other important prognostic biomarkers. Our results revealed the oncogenic role of BUB1B in THCA through series of bioinformatics and functional assays.

Abbreviations

THCA: thyroid carcinoma; BUB1B: BUB1 mitotic checkpoint serine/threonine kinase B; KEGG: Kyoto Encyclopedia of Genes and Genomes; GSEA: gene set enrichment analysis; PFS: progression-free survival; OS: overall survival; mTOR: mammalian target of rapamycin; NF-kappa B: nuclear factor kappa B; GSCA: Gene Set Cancer Analysis; TOP2A: Topoisomerase (DNA) II Alpha; BP: biological process; CC: cellular component; MF: molecular function; OD: optical density.

Acknowledgements

This research was funded by National Natural Science Foundation of China, grant number: 81701727.

Ethics Committee Approval

The study was approved by the Ethics Committee of The Second Affiliated Hospital of Zhejiang University College of Medicine.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Lv C, Sun W, Huang J, Qin Y, Ji X, Zhang H. Expression Profiles of Circular RNAs in Human Papillary Thyroid Carcinoma Based on RNA Deep Sequencing. OncoTargets and therapy. 2021; 14: 3821-32.
2. Stephen JK, Chitale D, Narra V, Chen KM, Savhney R, Wrosham MJ. DNA methylation in thyroid tumorigenesis. Cancers. 2011; 3: 1732-43.
3. Rao SN, Zaferro M, Dadu R, Busaidy NL, Hess K, Cote GJ, et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association. 2017; 27: 672-81.
4. Zhao J, Wen J, Wang S, Yao J, Liao L, Dong J. Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies. BMC cancer. 2020; 20: 788.
5. Lv L, Cao L, Hu G, Shen Q, Wu J. Methylation-Driven Genes Identified as Novel Prognostic Indicators for Thyroid Carcinoma. Frontiers in genetics. 2020; 11: 294.
6. Ma Y, Yin S, Liu XF, Hu J, Cai N, Zhang XB, et al. Comprehensive Analysis of the Functions and Prognostic Value of RNA-Binding Proteins in Thyroid Cancer. Frontiers in oncology. 2021; 11: 625007.
7. Zhao G, Kang J, Xu G, Wei J, Wang X, Jing X, et al. Tunicamycin promotes metastasis through upregulating endoplasmic reticulum stress induced GRP78 expression in thyroid carcinoma. Cell & bioscience. 2020; 10: 115.
8. Liu CZ, Guo WP, Peng JB, Chen G, Lin P, Huang XL, et al. Clinical significance of CCNE2 protein and mRNA expression in thyroid cancer tissues. Advances in medical sciences. 2020; 65: 442-56.
11. Scintu M, Vitale R, Prencipe M, Gallo AP, Bonghi L, Valori VM, et al. Genomic instability and increased expression of BUBIB and MAD2L1 genes in ductal breast carcinoma. Cancer letters. 2007; 254: 296-307.

12. Tian JH, Mu LJ, Wang MY, Zeng J, Long GZ, Guan B, et al. BUBIB Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK. Anti-cancer agents in medicinal chemistry. 2020; 20: 1140-6.

13. Ding Y, Hubert CG, Herman J, Corrin P, Toledo CM, Skutt-Kakaria K, et al. Cancer-Specific Requirement for BUBIB/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer discovery. 2013; 3: 198-211.

14. Chen J, Liao Y, Fan X. Prognostic and clinicopathological value of BUBIB expression in patients with lung adenocarcinoma: a meta-analysis. Expert review of anticancer therapy. 2021; 21: 795-803.

15. Toolabi N, Dalir F, Mokhlesi A, Talkhabi M. Identification of key regulators associated with colon cancer prognosis and pathogenesis. Journal of cell communication and signaling. 2021. [Online ahead of print]

16. Zhou H, Yang Z, Yue J, Chen Y, Chen T, Mu T, et al. Identification of potential hub genes via bioinformatics analysis combined with experimental verification in colorectal cancer. Molecular carcinogenesis. 2020; 59: 425-38.

17. Ma H, He Z, Chen J, Zhang X, Song P. Identifying of biomarkers associated with gastric cancer based on 11 topological analysis methods of CytoHubba. Scientific reports. 2021; 11: 1331.

18. Bi N, Sun Y, Lei S, Zeng Z, Zhang Y, Sun C, et al. Identification of 405 ribosomal protein S8 as a novel biomarker for alcohol-associated hepatocellular carcinoma using weighted gene coexpression network analysis. Oncology reports. 2020; 44: 611-7.

19. Fragoso MC, Almeida MQ, Mazzuco TL, Mariani BM, Brito LP, Gonçalves TC, et al. Combined expression of BUBIB, DLGAP5, and PINK1 as predictors of poor outcome in adenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. European journal of endocrinology. 2012; 166: 61-7.

20. Ding YG, Ren YL, Xu XS, Wei CS, Zhang YB, Zhang SK, et al. Identification of key candidate genes and pathways in anaplastic thyroid cancer by bioinformatics analysis. American journal of otolaryngology. 2020; 41: 10243.

21. Hu S, Liao Y, Chen L. Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis. Medical science monitor : international medical journal of experimental and clinical research. 2018; 24: 6438-48.

22. Burum-Auensen E, DeAngelis PM, Schjølberg AR, Roislien J, Mjaland O, Clausen OP. Reduced level of the spindle checkpoint protein BUB1B is associated with aneuploidy in colorectal cancers. Cell proliferation. 2008; 41: 645-59.

23. Long Z, Wu T, Tian Q, Carlson LA, Wang W, Wu G. Expression and prognosis analyses of BUB1, BUBIB and BUB3 in human sarcoma. Aging. 2021; 13: 12395-409.

24. Koyuncu D, Sharma U, Goka ET, Lippman ME. Spindle assembly checkpoint gene BUBIB is essential in breast cancer cell survival. Breast cancer research and treatment. 2021; 185: 331-41.

25. Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, et al. BUBIB promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer medicine. 2020; 9: 8159-72.

26. Hanks S, Coleman K, Summersgill B, Messahel B, Williamson D, Pritchard-Jones K, et al. Comparative genomic hybridization and BUBIB mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. Cancer letters. 2006; 239: 234-8.

27. Hahn MM, Vrede L, Bemelmans SA, van der Looij E, van Kessel AG, Pritchard-Jones K, et al. Comparative genomic hybridization and BUBIB mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. Cancer letters. 2006; 239: 234-8.

28. Rio Frió T, Lavoie J, Hamel N, Geyer FC, Kusner KB, Novak DJ, et al. Homozygous BUBIB mutation and susceptibility to gastrointestinal neoplasia. The New England journal of medicine. 2010; 363: 2628-37.

29. Bolanos-Garcia VM, Blundell TL. BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends in biochemical sciences. 2011; 36: 141-50.

30. Chen Q, Ke H, Luo X, Wang L, Wu Y, Tang S, et al. Rare deleterious BUBIB variants induce premature ovarian insufficiency and early menopause. Human molecular genetics. 2020; 29: 2698-707.

31. Hudler P, Britovsek NK, Grazio SF, Komel R. Association between polymorphisms in segregation genes BUBIB and TTK and gastric cancer risk. Radiology and oncology. 2016; 50: 297-307.

32. Zhao HB, Zeng YB, Han ZD, Zhuo YJ, Liang YK, Hon CT, et al. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma. Cancer science. 2021; 112: 4365-76.

33. Zhang Y, Wang X, Chen X. Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective. Aging. 2021; 13: 3112-45.

34. Jiang W, Xu J, Liao Z, Li G, Zhang C, Feng Y. Prognostic Signature for Lung Adenocarcinoma Patients Based on Cell-Cycle-Related Genes. Frontiers in cell and developmental biology. 2021; 9: 65990.

35. Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin ZY, et al. Overexpression of BUBIB contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. OncoTargets and therapy. 2016; 9: 221-20.

36. Harima Y, Ikeda K, Utsunomiya K, Shiga T, Komemushi A, Kojima H, et al. Identification of genes associated with progression and metastasis of advanced cervical cancers after radiotherapy by cDNA microarray analysis. International journal of radiation oncology, biology, physics. 2009; 75: 1232-9.

37. Ma Q, Liu Y, Shang I, Yu J, Qu Q. The FOXM1/BUBIB signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma. Oncology reports. 2017; 38: 3367-75.

38. Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, et al. Identification of FOXM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. Cancer research. 2012; 72: 5889-99.

39. He J, Wu J, Xu N, Xie W, Li M, Li J, et al. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic acids research. 2013; 41: 498-508.

https://www.jcancer.org